Lobular breast cancer: incidence and genetic and non-genetic risk factors
Open Access
- 13 March 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 17 (1), 37
- https://doi.org/10.1186/s13058-015-0546-7
Abstract
While most invasive breast cancers consist of carcinomas of the ductal type, about 10% are invasive lobular carcinomas. Invasive lobular and ductal carcinomas differ with respect to risk factors. Invasive lobular carcinoma is more strongly associated with exposure to female hormones, and therefore its incidence is more subject to variation. This is illustrated by US figures during the 1987 to 2004 period: after 12 years of increases, breast cancer incidence declined steadily from 1999 to 2004, reflecting among other causes the decreasing use of menopausal hormone therapy, and these variations were stronger for invasive lobular than for invasive ductal carcinoma. Similarly, invasive lobular carcinoma is more strongly associated with early menarche, late menopause and late age at first birth. As for genetic risk factors, four high-penetrance genes are tested in clinical practice when genetic susceptibility to breast cancer is suspected, BRCA1, BRCA2, TP53 and CDH1. Germline mutations in BRCA1 and TP53 are predominantly associated with invasive ductal carcinoma, while BRCA2 mutations are associated with both ductal and lobular cancers. CDH1, the gene coding for the E-cadherin adhesion protein, is of special interest as mutations are associated with invasive lobular carcinoma, but never with ductal carcinoma. It was initially known as the main susceptibility gene for gastric cancer of the diffuse type, but the excess of breast cancers of the lobular type in CDH1 families led researchers to identify it also as a susceptibility gene for invasive lobular carcinoma. The risk of invasive lobular carcinoma is high in female mutation carriers, as about 50% are expected to develop the disease. Carriers must therefore undergo intensive breast cancer screening, with, for example, yearly magnetic resonance imaging and mammogram starting at age 30 years.Keywords
This publication has 104 references indexed in Scilit:
- Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studiesThe Lancet Oncology, 2012
- Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trialThe Lancet Oncology, 2012
- Adhesion molecule signalling: not always a sticky businessNature Reviews Molecular Cell Biology, 2011
- Late age at first full term birth is strongly associated with lobular breast cancerCancer, 2010
- Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 statusBritish Journal of Cancer, 2010
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJama-Journal Of The American Medical Association, 2007
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Research and Treatment, 2007
- Established breast cancer risk factors by clinically important tumour characteristicsBritish Journal of Cancer, 2006
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995